In this control cohort, 79 patients (10%) carried a diagnosis of secondary Sjögren’s syndrome, 148 (19%) had anti-Ro/SSA antibodies, and 51 (7%) had anti-LA/SSB antibodies. Here, TRIM21 is linked to Sjogren syndrome.